Human Plasma Antigen Articles & Analysis
11 news found
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. The human leukocyte antigen (HLA) system plays a crucial role in immune regulation and determining transplantation compatibility. HLA typing, the process of identifying ...
CD Genomics is a leading global life sciences company committed to providing the research community with high-quality long-read sequencing services, from Oxford Nanopore to PacBio SMRT sequencing. The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient ...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer. Waisman Biomanufacturing has entered an agreement with BriaCell to ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is ...
These high quality products include a range of antigen products, normal human serum, disease state plasma, standards, positive control materials, and reagents for diagnostic tests such as buffers, catalysts, cofactors, blockers, substrates, stabilizers agents and solvents. ...
Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs™) and ...
Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS platform that ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
ASHI 2021 -- At the annual meeting for the American Society for Histocompatibility and Immunogenetics (ASHI) this week, Thermo Fisher Scientific announced two new additions to its transplant diagnostics portfolio. These new products will enable transplant laboratories to better characterize samples and bring speed and confidence to the transplant laboratory. More than 100,000 adults are now on a ...
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), ...